New Expert Consensus Pathway for Mitral Regurgitation

Share this content:
New Expert Consensus Pathway for Mitral Regurgitation
New Expert Consensus Pathway for Mitral Regurgitation

WEDNESDAY, Oct. 18, 2017 (HealthDay News) -- Identification of mitral regurgitation (MR) should prompt evaluation of its etiology, mechanism, severity, and indications for treatment, according to an expert consensus decision pathway published online Oct. 18 in the Journal of the American College of Cardiology.

Patrick T. O'Gara, M.D., from Harvard Medical School in Boston, and colleagues developed an expert consensus pathway to provide guidance for decision making in MR management.

The researchers note that the etiology, mechanism, and severity of MR should be defined after its identification; quantitative echocardiography and other testing should be used as necessary. For effective patient management, standardized echocardiographic reporting and timely access to accurate information are critical. To enable shared decision making, a heart valve team consensus treatment recommendation should be discussed with the patient and family; ongoing communication between members of the heart team and the referring provider is strongly endorsed. Use of transcatheter edge-to-edge repair is currently limited in the United States and is used in symptomatic patients with primary, severe MR who are poor operative candidates. Long-term follow-up of patients is essential for assessment of durability, functional outcomes, and survival.

"This expert consensus decision pathway provides the clinician with additional tools to improve the care of MR patients," the authors write. "It can serve as a guide to patient assessment and individualized decision making."

Several authors disclosed financial ties to the biopharmaceutical and medical device industries.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »